Indication
Gram-Positive Bacterial Infections
7 clinical trials
10 products
Clinical trial
An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Patients Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections (ORKIDS)Status: Recruiting, Estimated PCD: 2024-12-01
Product
OritavancinClinical trial
Phase 2, Double-Blind, Randomized, Multicenter, Parallel, Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection in AdultsStatus: Completed, Estimated PCD: 2020-09-28
Product
VancomycinProduct
TNP-2092Product
Contezolid acefosamilProduct
LinezolidClinical trial
A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil Compared to Linezolid Administered Intravenously and Orally to Adult Subjects With Acute Bacterial Skin and Skin Structure InfectionStatus: Completed, Estimated PCD: 2019-03-26
Clinical trial
Model-informed Precision Dosing for Linezolid: a Pilot Randomized Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2026-02-28
Clinical trial
Preliminary Evaluation of Dalbavancin's Efficacy in People Who Use Drugs With Severe Gram-positive InfectionsStatus: Terminated, Estimated PCD: 2023-10-05
Product
DalbavancinClinical trial
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
BedaquilineProduct
DelamanidProduct
ClofazimineProduct
Control arm MDR-TB regimenClinical trial
An Open-label, Pilot Clinical Trial of Dalbavancin for the Treatment of Susceptible Gram-positive Infections Requiring Prolonged Intravenous Antibiotic TherapyStatus: Withdrawn, Estimated PCD: 2025-04-01